BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

190 related articles for article (PubMed ID: 11907155)

  • 1. Elucidation of vasoactive intestinal peptide pharmacophore for VPAC(1) receptors in human, rat, and guinea pig.
    Igarashi H; Ito T; Hou W; Mantey SA; Pradhan TK; Ulrich CD; Hocart SJ; Coy DH; Jensen RT
    J Pharmacol Exp Ther; 2002 Apr; 301(1):37-50. PubMed ID: 11907155
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Elucidation of the vasoactive intestinal peptide pharmacophore for VPAC(2) receptors in human and rat and comparison to the pharmacophore for VPAC(1) receptors.
    Igarashi H; Ito T; Pradhan TK; Mantey SA; Hou W; Coy DH; Jensen RT
    J Pharmacol Exp Ther; 2002 Nov; 303(2):445-60. PubMed ID: 12388623
    [TBL] [Abstract][Full Text] [Related]  

  • 3. GI side-effects of a possible therapeutic GRF analogue in monkeys are likely due to VIP receptor agonist activity.
    Ito T; Igarashi H; Pradhan TK; Hou W; Mantey SA; Taylor JE; Murphy WA; Coy DH; Jensen RT
    Peptides; 2001 Jul; 22(7):1139-51. PubMed ID: 11445245
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Different vasoactive intestinal polypeptide receptor domains are involved in the selective recognition of two VPAC(2)-selective ligands.
    Juarranz MG; Van Rampelbergh J; Gourlet P; De Neef P; Cnudde J; Robberecht P; Waelbroeck M
    Mol Pharmacol; 1999 Dec; 56(6):1280-7. PubMed ID: 10570056
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Identification of key residues for interaction of vasoactive intestinal peptide with human VPAC1 and VPAC2 receptors and development of a highly selective VPAC1 receptor agonist. Alanine scanning and molecular modeling of the peptide.
    Nicole P; Lins L; Rouyer-Fessard C; Drouot C; Fulcrand P; Thomas A; Couvineau A; Martinez J; Brasseur R; Laburthe M
    J Biol Chem; 2000 Aug; 275(31):24003-12. PubMed ID: 10801840
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Two basic residues of the h-VPAC1 receptor second transmembrane helix are essential for ligand binding and signal transduction.
    Solano RM; Langer I; Perret J; Vertongen P; Juarranz MG; Robberecht P; Waelbroeck M
    J Biol Chem; 2001 Jan; 276(2):1084-8. PubMed ID: 11013258
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Development of simplified vasoactive intestinal peptide analogs with receptor selectivity and stability for human vasoactive intestinal peptide/pituitary adenylate cyclase-activating polypeptide receptors.
    Igarashi H; Ito T; Mantey SA; Pradhan TK; Hou W; Coy DH; Jensen RT
    J Pharmacol Exp Ther; 2005 Oct; 315(1):370-81. PubMed ID: 15994369
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Vasoactive intestinal polypeptide receptor VPAC(1) subtype is predominant in rat prostate membranes.
    Juarranz MG; De Neef P; Robberecht P
    Prostate; 1999 Sep; 41(1):1-6. PubMed ID: 10440869
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Creation of a selective antagonist and agonist of the rat VPAC(1) receptor using a combinatorial approach with vasoactive intestinal peptide 6-23 as template.
    Tams JW; Jorgensen RM; Holm A; Fahrenkrug J
    Mol Pharmacol; 2000 Nov; 58(5):1035-41. PubMed ID: 11040051
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Mutational analysis of the human vasoactive intestinal peptide receptor subtype VPAC(2): role of basic residues in the second transmembrane helix.
    Vertongen P; Solano RM; Perret J; Langer I; Robberecht P; Waelbroeck M
    Br J Pharmacol; 2001 Aug; 133(8):1249-54. PubMed ID: 11498510
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Development of selective agonists and antagonists for the human vasoactive intestinal polypeptide VPAC(2) receptor.
    Moreno D; Gourlet P; De Neef P; Cnudde J; Waelbroeck M; Robberecht P
    Peptides; 2000 Oct; 21(10):1543-9. PubMed ID: 11068102
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Two tyrosine residues in the first transmembrane helix of the human vasoactive intestinal peptide receptors play a role in supporting the active conformation.
    Perret J; Vertongen P; Solano RM; Langer I; Cnudde J; Robberecht P; Waelbroeck M
    Br J Pharmacol; 2002 Aug; 136(7):1042-8. PubMed ID: 12145104
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Evidence for a direct interaction between the Thr11 residue of vasoactive intestinal polypeptide and Tyr184 located in the first extracellular loop of the VPAC2 receptor.
    Nachtergael I; Vertongen P; Langer I; Perret J; Robberecht P; Waelbroeck M
    Biochem J; 2003 Mar; 370(Pt 3):1003-9. PubMed ID: 12475394
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Antagonistic actions of analogs related to growth hormone-releasing hormone (GHRH) on receptors for GHRH and vasoactive intestinal peptide on rat pituitary and pineal cells in vitro.
    Rekasi Z; Varga JL; Schally AV; Halmos G; Groot K; Czompoly T
    Proc Natl Acad Sci U S A; 2000 Feb; 97(3):1218-23. PubMed ID: 10655511
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Characterization of a novel VPAC(1) selective agonist and identification of the receptor domains implicated in the carboxyl-terminal peptide recognition.
    Van Rampelbergh J; Juarranz MG; Perret J; Bondue A; Solano RM; Delporte C; De Neef P; Robberecht P; Waelbroeck M
    Br J Pharmacol; 2000 Jun; 130(4):819-26. PubMed ID: 10864888
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Ac His1 [D-Phe2, K15, R16, L27] VIP (3-7)/GRF (8-27)--a VPAC1 receptor antagonist--is an inverse agonist on two constitutively active truncated VPAC1 receptors.
    Vertongen P; Langlet C; Langer I; Gaspard N; Robberecht P
    Peptides; 2004 Nov; 25(11):1943-9. PubMed ID: 15501526
    [TBL] [Abstract][Full Text] [Related]  

  • 17. VIP activates G(s) and G(i3) in rat alveolar macrophages and G(s) in HEK293 cells transfected with the human VPAC(1) receptor.
    Shreeve SM; Sreedharan SP; Hacker MP; Gannon DE; Morgan MJ
    Biochem Biophys Res Commun; 2000 Jun; 272(3):922-8. PubMed ID: 10860852
    [TBL] [Abstract][Full Text] [Related]  

  • 18. A novel vasoactive intestinal peptide (VIP) from elasmobranch intestine has full affinity for mammalian pancreatic VIP receptors.
    Dimaline R; Young J; Thwaites DT; Lee CM; Shuttleworth TJ; Thorndyke MC
    Biochim Biophys Acta; 1987 Aug; 930(1):97-100. PubMed ID: 2441759
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Photoaffinity labeling demonstrates physical contact between vasoactive intestinal peptide and the N-terminal ectodomain of the human VPAC1 receptor.
    Tan YV; Couvineau A; Van Rampelbergh J; Laburthe M
    J Biol Chem; 2003 Sep; 278(38):36531-6. PubMed ID: 12807902
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Identification of a VIP-specific receptor in guinea pig tenia coli.
    Teng BQ; Grider JR; Murthy KS
    Am J Physiol Gastrointest Liver Physiol; 2001 Sep; 281(3):G718-25. PubMed ID: 11518684
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 10.